Tempus AI Stock Jumps as FDA Clears New Cancer-Testing Device
Tempus AI shares rallied Monday after U.S. regulators cleared its latest cancer-testing device.The approval marks a key milestone that could accelerate new drug trials and widen the company’s reach in oncology. Key Takeaways Tempus AI stock rose more than 5% Monday after the FDA granted … Read more